| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.8 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |